Cite
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children.
MLA
Cleary, Yumi, et al. “Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children.” Clinical Pharmacokinetics, vol. 62, no. 6, June 2023, pp. 891–904. EBSCOhost, https://doi.org/10.1007/s40262-023-01241-7.
APA
Cleary, Y., Kletzl, H., Grimsey, P., Heinig, K., Ogungbenro, K., Silber Baumann, H. E., Frey, N., Aarons, L., Galetin, A., & Gertz, M. (2023). Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children. Clinical Pharmacokinetics, 62(6), 891–904. https://doi.org/10.1007/s40262-023-01241-7
Chicago
Cleary, Yumi, Heidemarie Kletzl, Paul Grimsey, Katja Heinig, Kayode Ogungbenro, Hanna Elisabeth Silber Baumann, Nicolas Frey, Leon Aarons, Aleksandra Galetin, and Michael Gertz. 2023. “Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children.” Clinical Pharmacokinetics 62 (6): 891–904. doi:10.1007/s40262-023-01241-7.